The p.R229Q variant of the NPHS2 (podocin) gene in focal segmental glomerulosclerosis and steroid-resistant nephrotic syndrome: a meta-analysis
- PMID: 24715228
- DOI: 10.1007/s11255-014-0676-3
The p.R229Q variant of the NPHS2 (podocin) gene in focal segmental glomerulosclerosis and steroid-resistant nephrotic syndrome: a meta-analysis
Abstract
While many previous studies have reported an association between the p.R229Q variant of the NPHS2 gene and focal segmental glomerulosclerosis (FSGS) or steroid-resistant nephrotic syndrome (SRNS), a conclusive relationship has not been defined. In this study, we performed a meta-analysis of the published data to investigate the impact of the p.R229Q polymorphism on FSGS and SRNS patients. Despite significant heterogeneity within some of the comparisons, the results revealed significantly higher risks of SRNS in individuals homozygous for the variant allele (OR 7.411, 95% confidence interval 1.876-29.436, p = 0.004) compared to homozygous non-variant individuals. However, the carrier rate of the p.R229Q variant was not significantly different between SRNS patients and steroid-sensitive nephrotic syndrome patients. No statistically significant differences in the p.R229Q carrier rate were observed between FSGS patients and controls or FSGS patients and patients with different pathology classifications. No notable differences in the p.R229Q carrier rate were found between patients and controls in any group with early-onset disease (onset age < 18). In conclusion, our meta-analysis suggests that for adult-onset disease (onset age > 18), the homozygous variant could be a potential predictor of hereditary nephrotic syndrome and that the p.R229Q allele cannot currently be considered a risk factor for predicting FSGS.
Similar articles
-
Association Between NPHS2 p.R229Q and Focal Segmental Glomerular Sclerosis/Steroid-Resistant Nephrotic Syndrome.Front Med (Lausanne). 2022 Jul 22;9:937122. doi: 10.3389/fmed.2022.937122. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35935761 Free PMC article.
-
Clinical value of NPHS2 analysis in early- and adult-onset steroid-resistant nephrotic syndrome.Clin J Am Soc Nephrol. 2011 Feb;6(2):344-54. doi: 10.2215/CJN.03770410. Epub 2010 Oct 14. Clin J Am Soc Nephrol. 2011. PMID: 20947785 Free PMC article.
-
R229Q polymorphism of NPHS2 gene in patients with late-onset steroid-resistance nephrotic syndrome: a preliminary study.Iran J Kidney Dis. 2013 Sep;7(5):399-403. Iran J Kidney Dis. 2013. PMID: 24072153
-
NPHS2 gene, nephrotic syndrome and focal segmental glomerulosclerosis: a HuGE review.Genet Med. 2006 Feb;8(2):63-75. doi: 10.1097/01.gim.0000200947.09626.1c. Genet Med. 2006. PMID: 16481888 Review.
-
The mutation-dependent pathogenicity of NPHS2 p.R229Q: A guide for clinical assessment.Hum Mutat. 2018 Dec;39(12):1854-1860. doi: 10.1002/humu.23660. Epub 2018 Oct 22. Hum Mutat. 2018. PMID: 30260545 Review.
Cited by
-
Association Between NPHS2 p.R229Q and Focal Segmental Glomerular Sclerosis/Steroid-Resistant Nephrotic Syndrome.Front Med (Lausanne). 2022 Jul 22;9:937122. doi: 10.3389/fmed.2022.937122. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35935761 Free PMC article.
-
Prevalence of NPHS2 gene R229Q polymorphism in Bangladeshi children with nephrotic syndrome.Heliyon. 2020 Oct 20;6(10):e05317. doi: 10.1016/j.heliyon.2020.e05317. eCollection 2020 Oct. Heliyon. 2020. PMID: 33102883 Free PMC article.
-
Non-collagen genes role in digenic Alport syndrome.BMC Nephrol. 2019 Feb 26;20(1):70. doi: 10.1186/s12882-019-1258-5. BMC Nephrol. 2019. PMID: 30808327 Free PMC article.
-
Variability in phenotype induced by the podocin variant R229Q plus a single pathogenic mutation.Clin Kidney J. 2015 Oct;8(5):538-42. doi: 10.1093/ckj/sfv063. Epub 2015 Jul 20. Clin Kidney J. 2015. PMID: 26413278 Free PMC article.
References
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
